- Home
- MXCT
MXCT
MaxCyte Inc.
as 11-07-2024 4:00pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 398.3M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 353.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.15 - $5.55 | Next Earning Date: | 11-06-2024 |
| Revenue: | $45,599,000 | Revenue Growth: | 19.85% |
| Revenue Growth (this year): | -8.79% | Revenue Growth (next year): | 23.47% |
Stock Insider Trading Activity of MaxCyte Inc. (MXCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Johnston John Joseph | MXCT | Director | Oct 28 '24 | Sell | $3.72 | 3,000 | $11,166.00 | 141,950 | |
| Erck Stanley C | MXCT | Director | Oct 1 '24 | Sell | $3.75 | 47,689 | $178,751.93 | 269,118 | |
| Johnston John Joseph | MXCT | Director | Sep 26 '24 | Sell | $3.82 | 3,000 | $11,460.00 | 141,950 | |
| Erck Stanley C | MXCT | Director | Sep 3 '24 | Sell | $4.04 | 47,689 | $191,655.19 | 269,118 | |
| Johnston John Joseph | MXCT | Director | Aug 26 '24 | Sell | $4.28 | 3,000 | $12,840.00 | 141,950 |
Latest MaxCyte Inc. News
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
GuruFocus.com
12 hours ago
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...
Zacks
a day ago
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
a day ago
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
GlobeNewswire
8 days ago
MaxCyte to Participate in Two Upcoming Investor Conferences
Simply Wall St.
9 days ago
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company
Zacks
23 days ago
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?
GlobeNewswire
24 days ago
MaxCyte Appoints Cynthia Collins to its Board of Directors
GlobeNewswire
a month ago
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
Compare MXCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.